Radiation Oncology
-
Questions Remain Following Long-Term Results of the Phase II SABR-COMET Trial
In Response To: Palma DA, Olson R, Harrow, S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. […]
-
The Immune System: A New Organ at Risk in Lung Cancer Radiation Therapy?
IN REFERENCE TO: Ladbury CJ, Rusthoven CG, Camidge DR, Kavanagh BD, Nath SK. Impact of radiation dose to the host immune system on tumor control and survival for stage III […]
-
Understanding the Promising Role of Stereotactic Ablative Radiotherapy in Treating Patients With Oligometastatic Disease
The recently published long-term results of the SABR-COMET phase II trial have further invigorated treatment options for patients with oligometastatic cancer.1 The early results of the SABR-COMET trial published in […]
-
Cardiac Radiation Dose, Cardiac Events, and Survival in Locally Advanced NSCLC
Megan Daly The standard of care for fit patients with unresectable, locally advanced (LA-) NSCLC is concurrent chemoradiation (CRT) followed by consolidation durvalumab. However, thoracic radiation (RT) for lung cancer […]
-
Brain Metastases in NSCLC: Is Delaying Upfront Radiation a Viable Option?
By Arya Amini, MD, and Chad G. Rusthoven, MD Posted: August 19, 2020 Approximately 10% of patients diagnosed with metastatic NSCLC present with brain metastases, and another 30% develop brain […]
-
PCI Decreases the Risk of Brain Metastases in Patients with Locally Advanced NSCLC
By Elizabeth Gore, MD Posted: May 27, 2019 IN REFERENCE TO: De Ruysscher D, Dingemans AC, Praag J, et al. Prophylactic cranial irradiation versus observation in radically treated stage III non-small-cell […]
-
Prophylactic Cranial Irradiation in Locally Advanced NSCLC Falls Flat
By John Armstrong, MD, FRCPI, DABR, FFRRCSI Posted: December 2018 RTOG 0214, a phase III randomized trial, is the biggest trial to date testing prophylactic cranial irradiation (PCI) in locally […]
-
2018 ASTRO Guideline for Palliative Thoracic Radiation Therapy for NSCLC: The Balance Between Curative and Palliative Radiotherapy
By Shalini K. Vinod, MBBS, MD Posted: October 2018 The standard of care for patients with inoperable stage III NSCLC is curative radiotherapy and concurrent chemotherapy.1 However, there are numerous […]
-
Living in the “Gray Zone”: Entering a New Age in Radiation Therapy for Patients with Lung Cancer
Posted: October 2018 Patients with stage III or more advanced lung cancer tend to be older and less healthy than patients with other stage III cancers. Because of this, selection […]
-
The Role for Trimodality Therapy in Stage III NSCLC
By Leah Lawrence Posted: June 2018 The use of trimodality therapy—the combination of chemoradiotherapy followed by surgery—remains controversial for patients with locally advanced cN2-N3 NSCLC. According to the National Comprehensive […]
View ILCN Archives
Provider Resources